01 1Cambrex Corporation
01 1RIVASTIGMINE
01 1U.S.A
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2017-09-28
Pay. Date : 2016-09-23
DMF Number : 29826
Submission : 2015-09-08
Status : Active
Type : II
20
Cambrex Karlskoga Ab, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for Cambrex is an innovative life sciences company with a refreshingly human approach.
One of their notable products is RIVASTIGMINE, with a corresponding US DMF Number 29826.
Remarkably, this DMF maintains an Active status since its submission on September 08, 2015, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of September 28, 2017, and payment made on September 23, 2016, indicating their dedication to facilitating drug approvals, Categorized as Type II
